PEDIATRIC HEMATOLOGY AND ONCOLOGY

Scope & Guideline

Elevating standards in pediatric hematology and oncology.

Introduction

Explore the comprehensive scope of PEDIATRIC HEMATOLOGY AND ONCOLOGY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore PEDIATRIC HEMATOLOGY AND ONCOLOGY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0888-0018
PublisherTAYLOR & FRANCIS INC
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1984 to 2024
AbbreviationPEDIATR HEMAT ONCOL / Pediatr. Hematol. Oncol.
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106

Aims and Scopes

Pediatric Hematology and Oncology focuses on the comprehensive understanding and treatment of blood disorders and cancers in children. The journal aims to disseminate innovative research, clinical findings, and reviews that improve the knowledge and practices within this specialized field.
  1. Pediatric Hematology:
    Research on various hematological disorders affecting children, including anemia, sickle cell disease, and hemophilia, with an emphasis on pathophysiology, treatment modalities, and long-term outcomes.
  2. Oncological Studies:
    Focused studies on pediatric cancers, including leukemia, lymphoma, and solid tumors, exploring diagnosis, treatment strategies, clinical trials, and survivorship.
  3. Transplantation and Cellular Therapies:
    Investigation into hematopoietic stem cell transplantation and other cellular therapies as treatment options for pediatric patients with severe hematological malignancies.
  4. Genetic and Molecular Research:
    Studies examining the genetic underpinnings of pediatric diseases, including genetic disorders, cancer predisposition, and the role of molecular markers in treatment responses.
  5. Supportive Care and Quality of Life:
    Research addressing supportive care measures, psychosocial aspects, and quality of life outcomes for pediatric patients and their families throughout treatment and survivorship.
  6. International Health and Disparities:
    Exploration of the challenges and outcomes of pediatric hematology and oncology in low- and middle-income countries, focusing on access to care and treatment disparities.
The journal has seen a rise in interest in several innovative and critical areas of research that reflect the evolving landscape of pediatric hematology and oncology. These emerging themes are crucial in shaping future research directions and clinical practices.
  1. Precision Medicine and Genetic Testing:
    An increasing number of papers focus on the application of genetic testing and precision medicine approaches to tailor treatments for pediatric patients, indicating a significant trend towards personalized healthcare.
  2. Impact of COVID-19 on Pediatric Patients:
    Research examining the effects of the COVID-19 pandemic on pediatric hematology and oncology patients is on the rise, highlighting the need for understanding how global health crises affect care delivery and patient outcomes.
  3. Innovative Supportive Care Strategies:
    Emerging studies are focusing on supportive care interventions, including psychosocial support and palliative care, which are crucial for improving the quality of life for pediatric patients and their families.
  4. Long-Term Outcomes and Survivorship:
    There is a growing emphasis on the long-term health outcomes and survivorship issues faced by pediatric cancer survivors, reflecting a shift towards recognizing the importance of post-treatment quality of life.
  5. International Collaborative Research:
    An increase in multicenter and international studies indicates a trend towards collaborative research efforts, aiming to address global disparities in pediatric cancer care and outcomes.

Declining or Waning

While certain research areas continue to thrive, others appear to be declining in prominence within the journal. This may reflect shifting priorities in pediatric hematology and oncology or changes in research funding and interest.
  1. Traditional Chemotherapy Approaches:
    There seems to be a decrease in studies focusing solely on conventional chemotherapy regimens, as newer targeted therapies and immunotherapies gain more attention in the treatment of pediatric cancers.
  2. Single-Center Studies:
    A noticeable decline in the publication of single-center studies suggests a shift towards multicenter collaborations that provide broader data and insights into treatment outcomes.
  3. Basic Science and Laboratory Studies:
    Research papers focusing on basic science and laboratory methodologies appear to be waning as clinical applications and translational research take precedence, highlighting a move towards practical and immediate clinical relevance.

Similar Journals

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Advancing pediatric care through groundbreaking research.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1077-4114Frequency: 8 issues/year

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

Turkish Journal of Hematology

Pioneering insights into blood disorders and treatments.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Hematology-American Society of Hematology Education Program

Exploring Innovations in Hematological Science
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi

Catalyzing progress in hematological and oncological science.
Publisher: AKAD DOKTORLAR YAYINEVIISSN: 1306-133XFrequency: 4 issues/year

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, published by AKAD DOKTORLAR YAYINEVI, is a pivotal journal in the fields of hematology and oncology, catering to an international audience of researchers, clinicians, and students. Since its inception in 2005, the journal has committed to disseminating high-quality, peer-reviewed research, highlighting advancements and challenges in the diagnosis and treatment of hematological and oncological disorders. Registered under ISSN 1306-133X, it serves as a significant platform for scholarly discourse, despite its recent categorization in the Q4 quartile for both hematology and oncology—indicating opportunities for growth and contribution within the scientific community. While currently not Open Access, the journal's indexed contribution to Scopus ranks it within the 12th and 17th percentiles in the domains of hematology and oncology respectively, reflecting its emerging presence within the academic landscape. As it approaches its convergence point in 2024, UHOD strives to elevate its influence, providing invaluable insights and fostering collaborations in the ongoing fight against blood disorders and cancer.

Blood Cancer Journal

Fostering collaboration in the fight against blood cancer.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

Journal of Adolescent and Young Adult Oncology

Pioneering Research for a Brighter Future in Oncology
Publisher: MARY ANN LIEBERT, INCISSN: 2156-5333Frequency: 6 issues/year

The Journal of Adolescent and Young Adult Oncology, published by MARY ANN LIEBERT, INC, is a premier peer-reviewed journal dedicated to enhancing the understanding and treatment of cancers in adolescents and young adults. With an ISSN of 2156-5333 and an E-ISSN of 2156-535X, this journal specializes in providing vital insights into the unique challenges faced by younger cancer patients, promoting research and clinical best practices in this underrepresented population. The journal features a commendable ranking in the Q2 quartile for Oncology and Q1 quartile for Pediatrics, Perinatology, and Child Health—highlighting its impact and relevance in both fields. Its Scopus rankings also reflect a strong standing; positioned at Rank #107/330 in Pediatrics and Rank #225/404 in Oncology. While the journal operates under a subscription-based model, it aims to disseminate crucial research findings and innovative treatments through its engaging content that serves as an invaluable resource for researchers, clinicians, and students alike. Since its inception in 2014, the journal has been at the forefront of addressing the pressing issues pertinent to young cancer patients, making it a vital outlet for groundbreaking studies and clinical advancements within this critical area of healthcare.

Journal of Hematology & Oncology

Transforming Insights into Impactful Treatments
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

BLOOD REVIEWS

Advancing the frontiers of Hematology and Oncology.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

ACTA HAEMATOLOGICA

Fostering Innovation in Blood Science Research
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

Egyptian Journal of Haematology

Empowering Hematologists with Cutting-Edge Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.